1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 3,920 | 4,000 | 21:52 | |
| 3,920 | 4,000 | 21:52 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 12.11. | Cytek Biosciences, Inc.: TIME Recognizes Cytek Biosciences as One of America's Growth Leaders of 2026 | 4 | GlobeNewswire (USA) | ||
| 06.11. | Cytek Biosciences, Inc.: Cytek Muse Micro Cell Analyzer Wins BioTech Breakthrough Award for Drug Discovery Solution of the Year | 4 | GlobeNewswire (USA) | ||
| 06.11. | Cytek reaffirms $196M-$205M 2025 revenue outlook as recurring businesses accelerate | 2 | Seeking Alpha | ||
| 05.11. | Cytek Biosciences GAAP EPS of -$0.04 beats by $0.01, revenue of $52.3M beats by $1.16M | 5 | Seeking Alpha | ||
| 05.11. | Cytek Biosciences, Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 29.10. | Cytek Biosciences, Inc.: Cytek Biosciences Deepens Commitment to Expanding Access to Flow Cytometry | 1.138 | GlobeNewswire (Europe) | FREMONT, Calif., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Amid the reduction of various government grant programs and global economic challenges that have tightened research funding, Cytek Biosciences, Inc.... ► Artikel lesen | |
| 22.10. | Cytek Biosciences, Inc.: Cytek Biosciences to Report Third Quarter 2025 Financial Results on November 5, 2025 | 2 | GlobeNewswire (USA) | ||
| CYTEK BIOSCIENCES Aktie jetzt für 0€ handeln | |||||
| 16.10. | Cytek Biosciences Expands with New Facility in Amsterdam | 3 | Contract Pharma | ||
| 15.10. | Cytek Biosciences, Inc.: Cytek Biosciences Expands European Presence with New Facility in Amsterdam to Better Serve Customers and Drive Growth | 1 | GlobeNewswire (USA) | ||
| 14.08. | Cytek Biosciences auf dem UBS Summit: Einblicke in innovative Proteomik-Technologien | 6 | Investing.com Deutsch | ||
| 07.08. | Cytek narrows 2025 revenue outlook to $196M-$205M amid recurring revenue growth and new product launches | 1 | Seeking Alpha | ||
| 06.08. | Cytek Biosciences, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 06.08. | Cytek Biosciences, Inc. - 8-K, Current Report | 3 | SEC Filings | ||
| 24.07. | Cytek Biosciences, Inc. (CTKB): A Bull Case Theory | 2 | Insider Monkey | ||
| 23.07. | Cytek Biosciences, Inc.: Cytek Biosciences to Report Second Quarter 2025 Financial Results on August 6, 2025 | 1 | GlobeNewswire (USA) | ||
| 24.06. | Cytek Biosciences, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 18.03. | Cytek Biosciences, Inc.: Cytek Biosciences Expands Cell Analysis Offerings with the Affordable, User-Friendly Cytek Muse Micro System | 423 | GlobeNewswire (Europe) | FREMONT, Calif., March 18, 2025 (GLOBE NEWSWIRE) -- Today, Cytek Biosciences, Inc. (Nasdaq: CTKB) announced that it has added transformative capabilities to its iconic Cytek® Guava® Muse® cell analyzer... ► Artikel lesen |
17 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| MEDIGENE | 0,025 | -6,02 % | MEDIGENE AG stürzt ab - ich traue meinen Augen nicht! | ||
| BIOFRONTERA | 2,770 | +3,36 % | BIOFRONTERA AG: Jetzt kippt das Gleichgewicht! | ||
| CLINUVEL | 7,010 | +2,49 % | Clinuvel Pharmaceuticals Limited: CLINUVEL expands Singapore RD&I Centre to pioneer next-generation peptide therapies | EXECUTIVE SUMMARY VALLAURIX Research, Development & Innovation Centre to expand its existing facilities and capabilities core focus on accelerating development of liquid long-acting drug delivery... ► Artikel lesen | |
| EDITAS MEDICINE | 2,156 | -0,19 % | Editas Medicine, Inc.: Editas Medicine Nominates EDIT-401, an LDLR-Targeted Medicine, as Lead In Vivo Development Candidate | EDIT-401 achieved ~90% mean LDL-C reduction with single dose in non-human primates EDIT-401 on track for human proof-of-concept data by end of 2026 Strong cash position with operational runway into... ► Artikel lesen | |
| ASEP MEDICAL | 6,021 | -100,00 % | ASEP Medical Holdings Inc (2): Asep Medical amends 2024 MD&A | ||
| CELLECTAR BIOSCIENCES | 3,275 | -9,53 % | Cellectar Biosciences, Inc.: Cellectar Biosciences Reports Third Quarter 2025 Financial Results and Provides Corporate Update | Expects to Submit Conditional Marketing Approval Application in Europe for Iopofosine I 131 in Refractory (post-BTKi) Waldenstrom's Macroglobulinemia in 2026 Following Advice and Guidance from Scientific... ► Artikel lesen | |
| CARDIFF ONCOLOGY | 2,040 | 0,00 % | Cardiff Oncology, Inc.: Cardiff Oncology Announces Clinical Data from Investigator-Sponsored Trial with Onvansertib in Chronic Myelomonocytic Leukemia at ASH 2025 | ||
| CLEAN HARBORS | 203,40 | -1,26 % | Why Clean Harbors Stock Triumphed on Tuesday | ||
| SPERO THERAPEUTICS | 1,960 | -1,01 % | Spero Therapeutics, Inc.: Spero Therapeutics Announces Second Quarter 2025 Operating Results and Provides a Business Update | PIVOT-PO Phase 3 trial evaluating tebipenem Hbr in complicated urinary tract infection (cUTI) patients stopped early for efficacy following review by independent data monitoring committee (IDMC)Spero... ► Artikel lesen | |
| MESOBLAST | 1,500 | -4,46 % | Mesoblast (MESO) Sees Optimism From Analysts | ||
| CSTONE PHARMACEUTICALS | 0,630 | -5,26 % | CSTONE PHARMA-B (02616): VOLUNTARY ANNOUNCEMENT - CSTONE ANNOUNCES THE INCLUSION OF GAVRETO (PRALSETINIB) IN THE 2025 NATIONAL REIMBURSEMENT DRUG LIST | ||
| PROTALIX BIOTHERAPEUTICS | 1,490 | -2,61 % | Protalix BioTherapeutics, Inc.: Protalix BioTherapeutics Reports Third Quarter 2025 Financial and Business Results | Company to host conference call and webcast today at 8:00 a.m. EST
CARMIEL, Israel, Nov. 13, 2025 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American:... ► Artikel lesen | |
| LIR LIFE SCIENCES | 0,970 | -6,28 % | Lir Life Sciences startet neue Vergleichsstudie zu Hautpflastern für Adipositastherapien auf Basis von "GLP" und "GIP" | Lüdenscheid (ots) - Lir Life Sciences Corp. (ISIN: CA50206C1005 | WKN: A41QA9), im Folgenden "Lir" oder das "Unternehmen", gibt mit Freude den Abschluss des Studiendesigns für eine neue vergleichende... ► Artikel lesen | |
| PALVELLA THERAPEUTICS | 76,00 | -9,52 % | Palvella Therapeutics Inc.: Palvella Therapeutics Announces Positive Topline Results from Phase 2 TOIVA Clinical Trial of QTORIN 3.9% Rapamycin Anhydrous Gel (QTORIN rapamycin) for the Treatment of Cutaneous Venous Malformations, a Serious, ... | 73% of trial participants (11/15 participants) improved on the Overall Cutaneous Venous Malformations Investigator Global Assessment (Overall cVM-IGA) at Week 12; 67% of trial participants (10/15... ► Artikel lesen | |
| PURPLE BIOTECH | 0,760 | +0,58 % | PURPLE BIOTECH LTD. - 6-K, Report of foreign issuer |
CYTEK BIOSCIENCES INC gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 4,040 Euro und damit -2,42 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu CYTEK BIOSCIENCES INC finden Sie auf Wallstreet Online.